Penumbra, Inc. (NYSE:PEN) Director Bridget O’rourke sold 429 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $106.60, for a total transaction of $45,731.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Penumbra, Inc. (PEN) traded up $1.00 during mid-day trading on Wednesday, reaching $107.55. 122,200 shares of the company were exchanged, compared to its average volume of 193,572. Penumbra, Inc. has a twelve month low of $57.85 and a twelve month high of $116.35.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Tuesday, November 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.07. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $79.17 million. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The firm’s quarterly revenue was up 24.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.04) EPS. analysts anticipate that Penumbra, Inc. will post -0.15 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Penumbra, Inc. (PEN) Director Bridget O’rourke Sells 429 Shares” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.watchlistnews.com/penumbra-inc-pen-director-bridget-orourke-sells-429-shares/1720246.html.

Hedge funds have recently added to or reduced their stakes in the stock. First Trust Advisors LP increased its position in Penumbra by 811.1% in the 2nd quarter. First Trust Advisors LP now owns 22,113 shares of the company’s stock valued at $1,940,000 after acquiring an additional 19,686 shares during the period. Eagle Asset Management Inc. increased its position in Penumbra by 168.7% in the 2nd quarter. Eagle Asset Management Inc. now owns 510,918 shares of the company’s stock valued at $44,833,000 after acquiring an additional 320,794 shares during the period. American Century Companies Inc. acquired a new position in Penumbra in the 2nd quarter valued at approximately $26,824,000. Vanguard Group Inc. increased its position in Penumbra by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,165,995 shares of the company’s stock valued at $190,066,000 after acquiring an additional 47,768 shares during the period. Finally, State Street Corp increased its position in Penumbra by 8.5% in the 1st quarter. State Street Corp now owns 512,470 shares of the company’s stock valued at $42,764,000 after acquiring an additional 40,271 shares during the period. Institutional investors and hedge funds own 72.73% of the company’s stock.

A number of analysts have recently weighed in on the stock. BidaskClub raised shares of Penumbra from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Zacks Investment Research cut shares of Penumbra from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. BMO Capital Markets upped their price objective on shares of Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $100.00 price objective (up from $94.00) on shares of Penumbra in a research report on Wednesday, August 9th.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.